Skip to main navigation Skip to search Skip to main content

Epidemiology, management, and burden of cytomegalovirus in solid organ transplant recipients in selected countries outside of Europe and North America: A systematic review

  • Helio Tedesco Silva Junior
  • , Yaman Tokat
  • , Jinzhen Cai
  • , Inderjeet Singh
  • , Anudeep Sandhu
  • , Dirk Demuth
  • , Jongman Kim
  • Universidade Federal de São Paulo
  • International Liver Center & Acibadem Healthcare Hospitals
  • Qingdao University
  • Takeda Biopharmaceuticals India Pvt. Ltd.
  • Takeda Pharmaceuticals International AG—Singapore Branch

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Cytomegalovirus (CMV) is a frequent infectious complication following solid organ transplantation (SOT). Considering significant differences in healthcare systems, a systematic review was conducted to describe the epidemiology, management, and burden of CMV post-SOT in selected countries outside of Europe and North America. Methods: MEDLINE, Embase, and Cochrane databases were searched for observational studies in SOT recipients across 15 countries in the regions of Asia, Pacific, and Latin America (search period: January 1, 2011 to September 17, 2021). Outcomes included incidence of CMV infection/disease, recurrence, risk factors, CMV-related mortality, treatment patterns and guidelines, refractory and/or resistant CMV, patient-reported outcomes, and economic burden. Results: Of 2708 studies identified, 49 were eligible (n = 43/49; 87.8% in adults; n = 34/49, 69.4% in kidney recipients). Across studies, selection of CMV preventive strategy was based on CMV serostatus. Overall, rates of CMV infection (within 1 year) and CMV disease post-SOT were respectively, 10.3%–63.2% (9 studies) and 0%–19.0% (17 studies). Recurrence occurred in 35.4%–41.0% cases (3 studies) and up to 5.3% recipients died of CMV-associated causes (11 studies). Conventional treatments for CMV infection/disease included ganciclovir (GCV) or valganciclovir. Up to 4.4% patients were resistant to treatment (3 studies); no studies reported on refractory CMV. Treatment-related adverse events with GCV included neutropenia (2%–29%), anemia (13%–48%), leukopenia (11%–37%), and thrombocytopenia (13%–24%). Data on economic burden were scarce. (Figure presented.). Conclusion: Outside of North America and Europe, rates of CMV infection/disease post-SOT are highly variable and CMV recurrence is frequent. CMV resistance and treatment-associated adverse events, including myelosuppression, highlight unmet needs with conventional therapy.

Original languageEnglish
Article numbere14070
JournalTransplant Infectious Disease
Volume25
Issue number4
DOIs
StatePublished - Aug 2023

Keywords

  • cytomegalovirus
  • disease burden
  • emerging markets
  • epidemiology
  • solid organ transplantation
  • systematic review

Fingerprint

Dive into the research topics of 'Epidemiology, management, and burden of cytomegalovirus in solid organ transplant recipients in selected countries outside of Europe and North America: A systematic review'. Together they form a unique fingerprint.

Cite this